Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

被引：0
|
作者：
Glauce Cordeiro Ulhôa Tostes
Maria Rosário Cunha
Rosa Tsumeshiro Fukui
Márcia Regina Silva Correia
Dalva Marreiro Rocha
Rosa Ferreira dos Santos
Maria Elizabeth Rossi da Silva
机构：
[1] Universidade de São Paulo,Laboratório de Carboidratos e Radioimunoensaios LIM
来源：
Diabetology & Metabolic Syndrome | / 8卷
关键词：
Nateglinide; Rosiglitazone; GLP-1; Haemostatic factors; Inflammatory markers; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The effect of the GLP-1 receptor agonist liraglutide on heart rate and heart rate variability in patients with type-2 diabetes: a randomized double-blind placebo-controlled cross over study
    Kumarathurai, P.
    Anholm, C.
    Larsen, B. S.
    Olsen, R. H.
    Madsbad, S.
    Kristiansen, O.
    Nielsen, O. W.
    Haugaard, S. B.
    Sajadieh, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1094 - 1095
  • [42] Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials
    Jing Qin
    Li Song
    BMC Endocrine Disorders, 22
  • [43] Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials
    Qin, Jing
    Song, Li
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)
  • [44] The effect of exogenous GLUCAGON-LIKE PEPTIDE-1 (GLP-1)-(7-36) AMIDE on the glucose mediated insulin secretion: a dose-response study in patients with type 2 diabetes mellitus and control subjects
    Kjems, LL
    Madsbad, S
    DIABETES, 1999, 48 : A290 - A290
  • [45] Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
    Ratner, R. E.
    Rosenstock, J.
    Boka, G.
    DIABETIC MEDICINE, 2010, 27 (09) : 1024 - 1032
  • [46] Safety and pharmacodynamics of CJC-1134-PC, a novel GLP-1 receptor agonist, in patients with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blind, dose-escalation study
    Wang, Maggie
    Kipnes, Mark
    Matheson, Stephanie
    Wen, Stella
    Lawrence, Betty
    Thibaudeau, Karen
    Castaigne, Jean-Paul
    Ulich, Thomas
    DIABETES, 2007, 56 : A133 - A133
  • [47] TCF7L2 gene associates with loss of residual beta-cell function and postprandial GLP-1 in young patients with new onset type 1 diabetes. Results from the hvidoere study group
    Nielsen, Lotte B.
    Porksen, Sven
    Hoey, Hilary
    Kocova, Mirjana
    Schonle, Eugen
    De Beaufort, Carine
    Hougaard, Philip
    Pociot, Flemming
    Knip, Mikael
    Holst, Jens J.
    Hansen, Lars
    Mortensen, Henrik B.
    DIABETES, 2008, 57 : A465 - A465
  • [48] Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart
    Smits, Mark M.
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Danser, A. H. Jan
    ter Wee, Piet M.
    Diamant, Michaela
    Joles, Jaap A.
    van Raalte, Daniel H.
    DIABETES CARE, 2016, 39 (11) : 2042 - 2050
  • [49] THE EFFECTS OFTOFACITINIB IN SIMULTANEOUSLY IMPROVING GLYCAEMIC PARAMETERS AND INFLAMMATORY MARKERS IN RHEUMATOID ARTHRITIS PATIENTS WITH COMORBID TYPE 2 DIABETES. A PROOF-OF-CONCEPT, OPEN, PROSPECTIVE, CLINICAL STUDY
    Ruscitti, P.
    Di Muzio, C.
    Di Cola, I.
    Panahi, A. Shariat
    Sensini, F.
    Ursini, F.
    Iagnocco, A.
    Giacomelli, R.
    Cipriani, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83
  • [50] Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, controlled clinical trial
    Derosa, Giuseppe
    Cicero, Arrigo F. G.
    D'Angelo, Angela
    Gaddi, Antonio
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Salvadeo, Sibilla A. T.
    Pricolo, Fabio
    Ferrari, Ilaria
    Gravina, Alessia
    Ragonesi, Pietro D.
    CLINICAL THERAPEUTICS, 2006, 28 (05) : 679 - 688
12345